Kevin F Mclaughlin bought stock once, on Nov 19, 2025

Kevin F. McLaughlin is a corporate finance executive and board director with more than 40 years of financial and operating management experience across the biotech, high‑tech, and education sectors.( He serves as a Director of Vericel Corporation (VCEL) and has been a member of its board since January 2015, including service as chair of the Audit Committee.( As a Vericel insider, he has reported multiple Form 4 filings for equity transactions in Vericel stock, most recently involving option exercises and open‑market sales under a Rule 10b5‑1 trading plan.( In addition to Vericel, he has held board roles at companies such as Invivyd, Combined Therapeutics, Stealth Biotherapeutics, Decibel Therapeutics, and other biotech firms.(

McLaughlin’s executive career includes a key role in the growth of Acceleron Pharma Inc., where he served as Senior Vice President, Chief Financial Officer and Treasurer from 2010 until its acquisition by Merck & Co., Inc., helping guide the company from a private research‑focused business to a publicly traded commercial enterprise.( Earlier, he held senior leadership positions at PRAECIS Pharmaceuticals Incorporated, including CFO, COO, President, and CEO, where he was responsible for negotiating the sale of the company to GlaxoSmithKline.( His background also includes CFO roles at Qteros, co‑founding and serving as COO of Aptius Education, and senior finance roles at Prime Computer/Computervision.( McLaughlin holds a B.S. in Accounting and Physical Distribution Management from Northeastern University and an M.B.A. from Babson College’s F.W. Olin Graduate School of Business.(

Written by Perplexity from public sources.